Ideas

Empagliflozin (EMBA)-based therapy for Cardiac repair and myocardial infarction: Empagliflozin (EMBA) (trade name: Jardiance), a sodium-glucose cotransporter 2 inhibitor used in the treatment of TIIDM, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 15/February/2019,  7.37 am
Empagliflozin (EMBA)-based therapy for Cardiac repair and myocardial infarction: Empagliflozin (EMBA) (trade name: Jardiance), a sodium-glucose cotransporter 2 inhibitor used in the treatment of TIIDM, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 15/February/2019,  7.37 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Combinatorial therapy for Notch1-overexpressing Human cancers: A therapeutic mix encompassing  Metformin and Navitoclax/ABT-263 (MAN) inhibits the expression of Notch1, and adhesion molecule VCAM1, suppresses neutrophil infiltration and tumor cell adhesion to endothelium and prevents Notch1-driven metastasis via upregulation of its target gene, 15/February/2019, 7.26 am
Combinatorial therapy for Notch1-overexpressing Human cancers: A therapeutic mix encompassing  Metformin and Navitoclax/ABT-263 (MAN) inhibits the expression of Notch1, and adhesion molecule VCAM1, suppresses neutrophil infiltration and tumor cell adhesion to endothelium and prevents Notch1-driven metastasis via upregulation of its target gene, 15/February/2019, 7.26 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Vascular Signaling and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Vascular Biology, CBTM, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim,…

read more

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA ANSR  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 15/February/2019, 7.16 am
Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA ANSR  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 15/February/2019, 7.16 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School…

read more

Dapagliflozin-based therapy for Cardiac repair and myocardial infarction: Dapagliflozin (brand name: Forxiga, Farxiga), a sodium glucose cotransporter inhibitor used in the treatment of TIIDM, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 15/February/2019, 6.33 am
Dapagliflozin-based therapy for Cardiac repair and myocardial infarction: Dapagliflozin (brand name: Forxiga, Farxiga), a sodium glucose cotransporter inhibitor used in the treatment of TIIDM, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 15/February/2019, 6.33 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Combinatorial therapy for prostate cancer bone metastasis:  A pharmaceutical mixture encompassing Metformin and Navitoclax (MAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 15/February/2019, 6.21 am
Combinatorial therapy for prostate cancer bone metastasis:  A pharmaceutical mixture encompassing Metformin and Navitoclax (MAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 15/February/2019, 6.21 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA shows that “MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes…

read more

Molecular therapy for tuberculosis: Ezetimibe (brand name:Zetia, Ezetrol),  a drug used to lower blood cholesterol, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 14/February/2019, 11.23 pm
Molecular therapy for tuberculosis: Ezetimibe (brand name:Zetia, Ezetrol),  a drug used to lower blood cholesterol, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via upregulation of its target gene, 14/February/2019, 11.23 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Singapore Immunology Network, Agency for Science, Technology and Research, Singapore; and Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore shows…

read more
Start Typing